Archives

Chonky Kitties Beware: Ozempic for Cats Is on the Way

If your cat has reached a size best described as “majestically chonky,” science may soon have a solution that spares you from micromanaging every scoop. A weight-loss drug for cats, modeled after human medications like Ozempic, is now being tested in veterinary clinical trials. More than half of pet cats worldwide are estimated to be […]

Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy—a phase 2 randomized trial

Nature Communications, Published online: 14 December 2025; doi:10.1038/s41467-025-66167-z Semaglutide, a GLP-1 receptor agonist, may offer neuroprotective benefits after stroke, but its effects in large vessel occlusion (LVO) are unknown. Here the authors show, in a phase 2 randomized trial, that semaglutide is safe after endovascular therapy and may improve recovery in patients not receiving intravenous […]

“DPP- 4 inhibitor alleviates gut-brain axis Parkinsons disease pathology” – can dipeptidyl peptidase 4 inhibitors be repurposed as disease-modifying drugs for body-first Parkinsons disease patients?

In their manuscript, Jeong et al investigated the effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4is), in a rotenone-based mouse model of Parkinson’s disease (PD).1 The study explored the association between diabetes and PD, focusing on the potential therapeutic benefits of glucagon-like peptide-1 receptor (GLP-1-R) agonists,2 given that DPP-4is are hypoglycaemic agents that enhance the […]

Ozempic may offer a surprising bonus benefit for brain health

A new analysis suggests that people with type 2 diabetes who use GLP-1 medications like Ozempic, Trulicity or Victoza may be less likely to develop epilepsy than those taking DPP-4 inhibitors. Semaglutide showed the strongest connection to lowered risk. Researchers caution that the findings show an association, not proof of cause and effect. More rigorous […]

One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk

(MedPage Today) — Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma compared with GLP-1 drugs among patients with type 2 diabetes, a large retrospective cohort study suggested…

Biomedicines, Vol. 13, Pages 3079: Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes

Biomedicines, Vol. 13, Pages 3079: Added Value to GLP-1 Receptor Agonist: Intermittent Fasting and Lifestyle Modification to Improve Therapeutic Effects and Outcomes Biomedicines doi: 10.3390/biomedicines13123079 Authors: Dragos Cozma Cristina Văcărescu Claudiu Stoicescu Obesity remains a major global health challenge, with glucagon-like peptide-1 receptor agonists (GLP-1RAs) providing substantial yet sensitive benefits in weight reduction, glycemic control, […]

Effectiveness of Pre‐Transplant Dual GLP‐1 Receptor Agonist and SGLT2 Inhibitor Therapy on All‐Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target‐Trial Emulation

This target trial emulation in solid organ transplant candidates with obesity and type 2 diabetes evaluates whether pre-transplant dual therapy with GLP-1 receptor agonists plus SGLT2 inhibitors is associated with post-transplant mortality and kidney graft outcomes compared with monotherapy or usual care, using multinational electronic health records and extensive sensitivity analyses. Abstract Evidence on pre-transplant […]

New Weight-Loss Pills Could Arrive Sooner Than We Think

Yevgen_Rychko / Getty Images Millions of Americans have successfully lost weight with semaglutides, the game-changing class of drugs that includes Ozempic, Mounjaro, and Wegovy. Still, many others are holding out for GLP-1 medication to arrive in pill form—and they may not have to wait much longer. Orforglipron, a GLP-1 agonist administered as a pill, is […]